pelacarsen
Nucleic acidexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Jan 14, 2020 (NCT04023552)
Timeline
Indications
Mechanism of action
- Apolipoprotein A-IANTISENSE INHIBITOR
APOA1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06267560 | Phase 3 | Apr 24, 2024 | Novartis |
| NCT05646381 | Phase 2 | Apr 27, 2023 | Novartis |
| NCT05305664 | Phase 3 | Aug 19, 2022 | Novartis |
| NCT05548023 | Phase 3 | Apr 16, 2020 | Chinese University of Hong Kong |
| NCT04023552 | Phase 3 | Jan 14, 2020 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 2 | 2020 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1